MHRA Issues Safety Roundup Including Recalls for Flucloxacillin and Gabapentin

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a safety roundup for June 2026, including several medicine recalls and defect notifications. Notably, a Class 3 Medicines Recall was issued for Flamingo Pharma UK Ltd's Flucloxacillin Capsules BP 500mg due to incorrect Patient Information Leaflets (PILs). Additionally, a Class 4 Medicines Defect Notification was issued for Relonchem Limited's Gabapentin Relonchem 50mg/ml Oral Solution, also due to an outdated PIL. These actions are aimed at ensuring patient safety.

Context

The MHRA is responsible for regulating medicines and healthcare products in the UK. The agency regularly monitors the safety of medications and issues recalls or notifications when necessary. The recent recalls for Flucloxacillin and Gabapentin are part of ongoing efforts to address potential risks associated with medication use.

Why it matters

The MHRA's safety roundup highlights critical issues regarding medication safety and patient information accuracy. Ensuring that patients receive correct information is vital for safe medication use. Recalls and defect notifications serve to protect public health and maintain trust in healthcare products.

Implications

Patients using the recalled medications may need to consult healthcare providers for alternatives or further guidance. Healthcare professionals must remain vigilant in monitoring for any adverse effects related to these products. The recalls could lead to increased scrutiny of other medications and their information accuracy in the future.

What to watch

In the near term, it will be important to monitor how these recalls impact the availability of Flucloxacillin and Gabapentin in the market. The MHRA may provide further updates on the status of these products and any additional safety measures. Stakeholders, including healthcare providers and pharmacies, will need to stay informed about these developments.